Compugen is a clinical-stage therapeutic discovery and development company utilizing its predictive computational discovery platforms to identify drug targets and develop therapeutics in the field of cancer immunotherapy. Co.'s immuno-oncology pipeline consists of three clinical stage programs, targeting immune checkpoints it discovered computationally. COM701 is an anti-PVRIG antibody for the treatment of solid tumors. COM902 is a therapeutic antibody targeting TIGIT, developed internally and is undergoing a study to evaluate it in patients with advanced malignancies. BAY 1905254 is a therapeutic antibody targeting ILDR2 and is studies in patients with advanced solid tumors. The CGEN stock yearly return is shown above.
The yearly return on the CGEN stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2014 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the CGEN annual return calculation with any dividends reinvested as applicable (on ex-dates).
|